Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
3
×
Tags
boston blog main
boston top stories
detroit blog main
detroit top stories
drugs
3
×
life sciences
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
3
×
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
cancer
clinical trials
fda
indiana blog main
indiana top stories
jefferies
national
accelerator
age related macular degeneration
agios pharmaceuticals
airbnb
alder biopharmaceutical
allergan
amazon web services (aws)
american academy of neurology
american society of hematology
What
big
3
×
companies
meeting
admits
ago
american
approval
arguments
ash
biotechs
blood
class
classes
combinator
commercialized
competitors
country
decades
diego
disease
drug
drugs
dug
fda
gathering
hematology’s
incubator
largest
life
make
medical
migraine
neuro
new
oral
potential
previewed
previously
rolls
san
Language
unset
Current search:
big
×
photo
×
" san francisco blog main "
×
drugs
×
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On